Inflammasome-targeted RNA interference approach to treating kidney injury and disease
US12343407B2 · kind B2 · utility
0Cited by
3References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 26, 2020 |
| Grant date | Jul 1, 2025 |
| Priority date | — |
| Expiry date | Jul 7, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates generally to methods for treating, preventing, and/or ameliorating chronic kidney disease (CKD) and/or renal injury in a subject in need thereof. In particular, the methods disclosed herein comprise administering a therapeutically effective amount of a pharmaceutical composition comprising at least one Nlrp3 siRNA non-covalently conjugated to sidewall ammonium-functionalized carbon nanotubes (fCNTs), wherein the at least one Nlrp3 siRNA reduces the expression of NLR pyrin domain-containing protein 3 (NLRP3) in a subject diagnosed with, or at risk for CKD and/or renal injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.